Shares of Bone Biologics Corp. (BBLG) are currently gaining nearly 80% on Monday morning. Jeffrey Frelick, the company's president and chief executive officer, is set to present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 - 13, 2022.
BBLG is currently trading at $6.11, up $2.68 or 78.13%, on the Nasdaq, on a heavy volume of 31 million shares, above average volume of 565 thousand shares.
Bone Biologics is a medical device company that focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.
For comments and feedback: editorial@rttnews.com